Intelligence Report · ~15 min read
Nutraceuticals · Vitamin D Therapeutic Area Assessment
1 signals · 1 insights · 5 regulatory precedents
Type
Therapeutic Area AssessmentGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 67%
Evidence
7 items
Sources
1
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
Therapeutic area assessment for Nutraceuticals · Vitamin D integrates 1 signals, 1 executive insights, and 5 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.
Key Developments
Material intelligence events ranked by strategic relevance.
- signalJul 2, 2026
Novel GA/βCD/VDC Nanovehicle Enhances Oral Bioavailability of Cholecalciferol
The GA/βCD/VDC nanovehicle significantly enhances the oral bioavailability of cholecalciferol, improving absorption and retention in tissues.
View detail - regulatoryJul 2, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - regulatoryJul 2, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - regulatoryJul 2, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - regulatoryJul 2, 2026
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
View detail - insightJul 3, 2026
Innovative Nanovehicle Technology Enhances Vitamin D Bioavailability and Market Positioning
The development of the GA/βCD/VDC nanovehicle significantly enhances the oral bioavailability of cholecalciferol, positioning it favorably against existing vitamin D products. This innovation could lead to strategic partnerships and new product developments in the nutraceuticals and drug delivery sectors. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Executive insights surface 1 risk-calibrated assessments for portfolio review. 5 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 0 companies with active signal exposure for competitive and portfolio shifts.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
72%Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidenceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
72%Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidenceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
72%Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidenceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)
72%Application ANDA210671. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidenceFDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (PHARMACY BULK PACKAGE) (ORIG)
72%Application ANDA210456. Sponsor: APOTEX. Submission status: AP. Submission type: ORIG. Review priority: STANDARD. Active ingredients: ASCORBIC ACID, BIOTIN, CHOLECALCIFEROL, CYANOCOBALAMIN, DEXPANTHENOL, FOLIC ACID, NIACINAMIDE, PYRIDOXINE, RIBOFLAVIN, THIAMINE, TOCOPHEROL ACETATE, VITAMIN A, VITAMIN K.
Source: FDA
View evidenceInnovative Nanovehicle Technology Enhances Vitamin D Bioavailability and Market Positioning
67%The development of the GA/βCD/VDC nanovehicle significantly enhances the oral bioavailability of cholecalciferol, positioning it favorably against existing vitamin D products. This innovation could lead to strategic partnerships and new product developments in the nutraceuticals and drug delivery sectors. Regulatory context from FDA (FDA AP — MULTIPLE VITAMINS INJECTION PEDIATRIC (ORIG)) supports the near-term read. Assessment grounded in 21 ranked evidence items (10 high-relevance).
Source: Humanexa Insight
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Insights
- Innovative Nanovehicle Technology Enhances Vitamin D Bioavailability and Market Positioning
Nutraceuticals · Vitamin D